Adipokine blood profile in young people with comorbid pathology

The aim of study was to study the features of the adipokine blood profile in young people with comorbid pathology.
Material and methods. A cross-sectional population survey of Novosibirsk was conducted. The population sample included 1415 people, including 47 % of men. Comorbid pathology was considered a combination of 3 or more pathological conditions (CHD, AG, CB, hyperLDL-C, decreased renal function and type 2 diabetes). Adipokine levels in the blood were determined using the multiplex analysis method on a Milliplex multiplex analyzer (Merck, Millipore).
Results. When conducting a univariate logistic regression analysis, it was found that the presence of comorbid pathology was associated with an increase in amylin by 1 pg/ml (p < 0.0001), ghrelin by 1 pg/ml (p = 0.016), resistin by 1 ng/ml (p = 0.001), IL-6 by 1 pg/ml (p = 0.005), C-peptide by 1 ng/ml (p = 0.024) and a decrease in PYY by 1 pg/ml (p = 0.007). In multivariate regression analysis in model 1 (gender, age, OT, resistin, IL-6, and PYY), the chance of having comorbid pathology increased by 15 % with an increase in age by 1 year (p = 0.011) and by 2.5 % with a decrease in PYY by 1 pg/ml (p = 0.005); in model 2 (gender, age, WC, resistin, IL-6, and C-peptide), the chance of having a comorbid pathology increased by 13 % with an increase in age by 1 year (p = 0.001), by 0.1 % with an increase in resistin levels by 1 ng/ml (p = 0.046), by 12 % with an increase in IL-6 levels by 1 pg/ml (p = 0.041), and by 116 % with an increase in C-peptide levels by 1 ng/ml (p = 0.019).
Conclusions. In young people, the presence of comorbid pathology is associated with an increase in the blood of amylin, ghrelin and a decrease in the level of PYY, responsible for appetite regulation, as well as with an increase in the levels of resistin, IL-6 and C-peptide, involved in the formation of insulin resistance.

1. Chait A., den Hartigh L.J. Adipose tissue distribution, inflammation and its metabolic consequences, including diabetes and cardiovascular disease. Front. Cardiovasc. Med., 2020; 7: 22. doi: 10.3389/fcvm.2020.00022

2. Kwaifa I.K., Bahari H., Yong Y.K., Noor S.M. Endothelial dysfunction in obesity-induced inflammation: molecular mechanisms and clinical implications. Biomolecules, 2020; 10 (2): 291. doi: 10.3390/biom10020291

3. Ural D., Kiliçkap M., Göksülük H., Karaaslan D., Kayikçioǧlu M., Özer N., BarÇin C., Yilmaz M.B., Abaci A., Şengül Ş., Arinsoy T., Erdem Y., Sanisoǧlu Y., Şahin M., Tokgözoǧlu L. Data on prevalence of obesity and waist circumference in Turkey: Systematic review, meta-analysis and meta-regression of epidemiological studies on cardiovascular risk factors. Turk. Kardiyol. Dern. Ars., 2018; 46: 577–590. doi: 10.5543/tkda.2018.62200

4. Ha E.E., Bauer R.C. Emerging roles for adipose tissue in cardiovascular disease. Arterioscler. Thromb. Vasc. Biol., 2018; 38 (8): e137–e144. doi: 10.1161/ATVBAHA.118.311421

5. Carbone S., Canada J.M., Billingsley H.E., Siddiqui M.S., Elagizi A., Lavie C.J. Obesity paradox in cardiovascular disease: where do we stand? Vasc. Health Risk Manag., 2019; 15: 89–100. doi: 10.2147/VHRM.S168946

6. Dutheil F., Gordon B.A., Naughton G., Crendal E., Courteix D., Chaplais E., Thivel D., Lac G., Benson A.C. Cardiovascular risk of adipokines: a review. J. Int. Med. Res., 2018; 46 (6): 2082–2095. doi: 10.1177/0300060517706578

7. Khudiakova A.D., Polonskaya Yа.V., Shcherbakova L.V., Shramko V.S., Kuzminykh N.A., Kashtanova E.V., Ragino Yu.I. Associations of circulating adipokines and coronary artery disease in young adults. Cardiovascular Therapy and Prevention, 2024; 23 (5): 3965. (In Russ.). doi: 10.15829/1728-8800-2024-3965

8. Polonskaya Yа.V., Kashtanova E.V., Stakhneva E.M., Shramko V.S., Sadovski E.V., Shcherbakova L.V., Khudyakova A.D., Ragino Yu.I. The level of adipokines in young people with hypertension and abdominal obesity. Arterial Hypertension, 2023; 29 (1): 51–57. (In Russ.). doi: 10.18705/1607-419X-2022-28-6-51-57

9. Afanaseva A.D., Polonskaya Yа.V., Shramko V.S., Shcherbakova L.V., Kashtanova E.V., Ragino Yu.I. Associations of adipocytokines and kidney function in young people with abdominal obesity. Russian Jour-nal of Preventive Medicine, 2024; 27 (8): 53–59. (In Russ.). doi: 10.17116/profmed20242708153

10. Khudiakova A.D., Polonskaya Yа.V., Shramko V.S., Shcherbakova L.V., Striukova E.V., Kashtanova E.V., Ragino Yu.I. Blood adipokines/cytokines in young people with chronic bronchitis and abdominal obesity. Biomolecules, 2022; 12: 1502. doi: 10.3390/biom12101502

11. Ragino Yu., Polonskaya Ya., Spiridonov A., Striukova E., Shcherbakova L., Khudiakova A., Shramko V., Stakhneva E., Kashtanova E. Adipokines, metabolic hormones and their associations with abdominal obesity against a background of hyper-LDL-C in young people. J. Pers. Med., 2022; 12: 1823. doi: 10.3390/jpm12111823

12. Kashtanova E.V., Polonskaya Ya.V., Shcherbakova L.V., Stakhneva E.M., Shramko V.S., Mustafina S.V., Khudyakova A.D., Ragino Yu.I. Associations of adupocutokine and metaboliv hormone level in young people aged 25–44 years with type 2 diabetes mellitus and abdominal obesity. Obesity and metabolism, 2024; 21 (1): 14–23. (In Russ.). doi: 10.14341/omet12974

13. Kim O.T., Dadaeva V.A., Korolev A.I., Drapkina O.M. Perivascular adipose tissue in the pathogenesis of cardiovascular disease. Russian Journal of Cardiology, 2021; 26 (11): 4567. (In Russ.). doi: 10.15829/1560-4071-2021-4567

14. Kalinina A.M., Shalnova S.A., Gambaryan M.G., Yeganyan R.A., Muromtseva G.A., Bochkareva E.V., Kim I.V. Epidemiological methods for detecting major chronic noncommunicable diseases and risk factors in mass population surveys. Methodical manual. Moscow, 2015. 96 p. (In Russ.).

15. Borodkina D.A., Gruzdeva O.V., Belik E.V., Dyleva Yu.A., Palicheva E.I. Perivascular adipose tissue and atherosclerosis: phenotypic features and therapeutic potential. Ateroscleroz, 2020; 16 (2): 63–72. (In Russ.). doi: 10.15372/ATER20200206

16. Cheng K.H., Chu C.S., Lee K.T., Lin T.H., Hsieh C.C., Chiu C.C., Voon W.C., Sheu S.H., Lai W.T. Adipocytokines and proinflammatory mediators from abdominal and epicardial adipose tissue in patients with coronary artery disease. Int. J. Obes. (Lond). 2008; 32 (2): 268–274. doi:10.1038/sj.ijo.0803726

17. Sumithran P., Prendergast L.A., Delbridge E., Purcell K., Shulkes A., Kriketos A., Proietto J. Longterm persistence of hormonal adaptations to weight loss. N. Engl. J. Med., 2011; 365 (17): 1597–1604. doi: 10.1056/NEJMoa1105816

18. Ling W., Huang Y.M., Qiao Y.C., Zhang X.X., Zhao H.L. Human amylin: from pathology to physiology and pharmacology. Curr. Protein Pept. Sci., 2019; 20 (9): 944–957. doi: 10.2174/1389203720666190328111833

19. Tschöp M., Wawarta R., Riepl R.L., Friedrich S., Bidlingmaier M., Landgraf R., Folwaczny C. Postprandial decrease of circulating human ghrelin levels. J. Endocrinol. Invest., 2001; 24 (6): RC19–RC21. doi: 10.1007/BF03351037

20. Acquarone E., Monacelli F., Borghi R., Nencioni A., Odetti P. Resistin: A reappraisal. Mech. Ageing. Dev., 2019; 178: 46–63. doi: 10.1016/j.mad.2019.01.004

21. Jamaluddin M.S., Weakley S.M., Yao Q., Chen C. Resistin: functional roles and therapeutic considerations for cardiovascular disease. Br. J. Pharmacol., 2012; 165 (3): 622–632. doi: 10.1111/j.1476-5381.2011.01369.x

22. Rajala M.W., Qi Y., Patel H.R., Takahashi N., Banerjee R., Pajvani U.B., Sinha M.K., Gingerich R.L., Scherer P.E., Ahima R.S. Regulation of resistin expression and circulating levels in obesity, diabetes, and fasting. Diabetes, 2004; 53 (7): 1671–1679. doi: 10.2337/diabetes.53.7.1671

23. Banu S., Jabir N.R., Manjunath C.N., Shakil S., Kamal M.A. C-peptide and its correlation to parameters of insulin resistance in the metabolic syndrome. CNS Neurol. Disord. Drug Targets, 2011; 10 (8): 921–927. doi: 10.2174/187152711799219271

24. Heymsfield S.B., Wadden T.A. Mechanisms, pathophysiology, and management of obesity. N. Engl. J. Med., 2017; 376 (3): 254–266. doi: 10.1056/NEJMra1514009

25. Ullrich S.S., Otto B., Hutchison A.T., Luscombe-Marsh N.D., Horowitz M., Feinle-Bisset C. Comparative effects of intraduodenal protein and lipid on ghrelin, peptide YY, and leptin release in healthy men. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2015; 308 (4): R300–R304. doi: 10.1152/ajpregu.00504.2014

26. Chan J.L., Stoyneva V., Kelesidis T., Raciti P., Mantzoros C.S. Peptide YY levels are decreased by fasting and elevated following caloric intake but are not regulated by leptin. Diabetologia, 2006; 49: 169–173. doi: 10.1007/s00125-005-0041-2

27. Rizvi I.A., Robinson K., McFadden D.W., Riggs D.R., Jackson B.J, Vona-Davis L. Peptide YY reverses TNF-alpha induced transcription factor binding of interferon regulatory factor-1 and p53 in pancreatic acinar cells. J. Surg. Res., 2006; 136 (1): 25–30. doi: 10.1016/j.jss.2006.05.028